Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $19.4 million.

  • Corcept Therapeutics' Net Income towards Common Stockholders fell 5853.72% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.6 million, marking a year-over-year decrease of 2550.07%. This contributed to the annual value of $139.7 million for FY2024, which is 3245.34% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Net Income towards Common Stockholders stood at $19.4 million, which was down 5853.72% from $34.6 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Net Income towards Common Stockholders ranged from a high of $46.7 million in Q3 2024 and a low of $15.8 million during Q1 2023
  • Over the past 5 years, Corcept Therapeutics' median Net Income towards Common Stockholders value was $27.5 million (recorded in 2024), while the average stood at $28.1 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Net Income towards Common Stockholders soared by 8836.87% in 2023, and later plummeted by 5853.72% in 2025.
  • Over the past 5 years, Corcept Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $32.1 million in 2021, then crashed by 48.42% to $16.5 million in 2022, then soared by 88.37% to $31.1 million in 2023, then decreased by 2.42% to $30.4 million in 2024, then tumbled by 36.3% to $19.4 million in 2025.
  • Its last three reported values are $19.4 million in Q3 2025, $34.6 million for Q2 2025, and $20.3 million during Q1 2025.